Skip to main content
Top
Published in: Cancer and Metastasis Reviews 3/2023

06-10-2023

Preface

Authors: Ajeet Kaushik, Vijai Gupta

Published in: Cancer and Metastasis Reviews | Issue 3/2023

Login to get access

Excerpt

Cancer is still one of the top-ranked death-causing diseases which is continuously increasing globally. It is not only a serious concern to the health bus but also affects emotionally, and both patient and family are victims. Fortunately, the advancements in multidisciplinary biomedical sciences give hope to treat it if diagnosed at an early stage and further to manage it every detected at a mid- or later stage. In this direction, several anti-cancer drugs have been approved by the FDA and efforts are being made to investigate more drugs and explore others that can be integrated with treatment, monitoring, and diagnostics approaches, with the aim to manage cancer efficiently. To support and meet the demand, cancer treatment research and development will be occupying a market size of $365.99 billion by the year 2030. …
Metadata
Title
Preface
Authors
Ajeet Kaushik
Vijai Gupta
Publication date
06-10-2023
Publisher
Springer US
Published in
Cancer and Metastasis Reviews / Issue 3/2023
Print ISSN: 0167-7659
Electronic ISSN: 1573-7233
DOI
https://doi.org/10.1007/s10555-023-10140-z

Other articles of this Issue 3/2023

Cancer and Metastasis Reviews 3/2023 Go to the issue

Announcement

Biographies

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine